Drug Development
Heparin octasaccharides block angiogenesis in cancer models without affecting coagulation
Published in Blood Weekly, January 19th, 2006
"In previous experiments, we showed that heparin oligosaccharides inhibit the angiogenic cytokine fibroblast growth factor-2 (FGF-2). Here, we present the first in vivo study of size-fractionated heparin oligosaccharides in four models of angiogenesis that are progressively less dependent on FGF-2," investigators in England report.
"Heparin oligosaccharides were prepared using size-exclusion gel filtration chromatography and characterized through depolymerization and strong anion exchange high-performance liquid chromatography. Size-defined oligosaccharides (20...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
Source: Blood Weekly (2006-01-19)
More Articles from Blood Weekly
- Blood Safety
Modified procedure safe and effective for collection of cytokine-mobilized PBCs - Chronic Myeloid Leukemia
Imatinib mesylate enhances chronic myeloid leukemia stem cell elimination - Tissue Engineering
Composite tissue-engineered intervertebral discs similar to native tissue - Tissue Engineering
Perfusion bioreactor system produces clinically relevant volumes of tissue-engineered bone - Tissue Engineering
Trachea reconstructed from tissue engineered human hyaline cartilage - Acute Coronary Syndromes
Platelet hyperfunction is suggested in acute coronary syndromes - More from this issue of Blood Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
